down arrow

VistaGen Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92840H4002
USD
4.28
0.68 (18.89%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.744.32

52 Week

1.905.13
Valuation
Technical
Day's Volume

CASH

1.2 M

Shareholding (Dec 2024)

FII

4.31%

Held by 18 FIIs

DII

76.37%

Held by 12 DIIs

Promoter

9.64%

How big is VistaGen Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, VistaGen Therapeutics, Inc. has a market capitalization of 69.01 million and reported net sales of 0.69 million with a net loss of 47.30 million over the last four quarters. Shareholder's funds were 114.29 million, and total assets were 123.65 million.

As of Jun 18, VistaGen Therapeutics, Inc. has a market capitalization of 69.01 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.69 million for the latest four quarters, while the net profit for the same period was a loss of 47.30 million.<BR><BR>As of Mar 24, the company's shareholder's funds amounted to 114.29 million, and total assets were reported at 123.65 million.

Read More

What does VistaGen Therapeutics, Inc. do?

22-Jun-2025

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. It has a market cap of $69.01 million and reported no net sales with a net loss of $14 million as of December 2024.

Overview: <BR>VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -14 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 69.01 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.08 <BR>Return on Equity: -58.31% <BR>Price to Book: 0.85<BR><BR>Contact Details: <BR>Address: 343 Allerton Ave, SOUTH SAN FRANCISCO CA: 94080-4816 <BR>Tel: ['1 650 5773600', '1 212 8961254'] <BR>Website: https://www.vistagen.com/

Read More

Who are in the management team of VistaGen Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of VistaGen Therapeutics, Inc. includes Jon Saxe (Independent Chairman), Dr. H. Ralph Snodgrass (President and Chief Scientific Officer), Shawn Singh (CEO), and Independent Directors Ann Cunningham, Dr. Jerry Gin, and Dr. Brian Underdown. They oversee the company's strategic direction and operations.

As of March 2022, the management team of VistaGen Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Jon Saxe, who serves as the Independent Chairman of the Board.<BR>- Dr. H. Ralph Snodgrass, who is the President, Founder, Chief Scientific Officer, and a Director.<BR>- Mr. Shawn Singh, who holds the position of Chief Executive Officer and is also a Director.<BR>- Ms. Ann Cunningham, who is an Independent Director.<BR>- Dr. Jerry Gin, who is an Independent Director.<BR>- Dr. Brian Underdown, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is VistaGen Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, VistaGen Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor investment appeal due to a negative ROE and significant underperformance compared to the S&P 500.

As of 8 July 2024, the valuation grade for VistaGen Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.84 and an EV to EBITDA ratio of 0.37, which suggest that the market may not be accurately reflecting the underlying value of the company. Additionally, the ROCE stands at an impressive 773.04%, but this is overshadowed by a negative ROE of -58.31%, indicating challenges in generating returns for shareholders.<BR><BR>In comparison to its peers, VistaGen's valuation ratios are concerning, with Solid Biosciences, Inc. showing a worse EV to EBITDA of -0.8654 and Cognition Therapeutics, Inc. at -3.8036, both indicating significant struggles in profitability. The company's stock performance has also lagged behind the S&P 500, with a 5-year return of -84.27% compared to the index's 96.61%, reinforcing the notion that VistaGen is currently overvalued.

Read More

Is VistaGen Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, VistaGen Therapeutics, Inc. shows a bullish technical trend with mixed momentum indicators, underperforming the S&P 500 year-to-date and over the past year.

As of 26 August 2025, the technical trend for VistaGen Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, indicating positive momentum. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a bearish stance on the monthly timeframe. The KST is bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bullish trend in both weekly and monthly perspectives. The OBV presents a mixed view, being mildly bearish weekly but bullish monthly.<BR><BR>In terms of performance, VistaGen has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 3.05% versus 12.22% for the S&P 500, and a one-year return of 1.50% compared to 17.14% for the index. Overall, the current technical stance is bullish, but the strength is mixed, with some indicators showing caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 107 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-93.15%

stock-summary
Price to Book

1.89

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.99%
0%
15.99%
6 Months
79.08%
0%
79.08%
1 Year
58.52%
0%
58.52%
2 Years
17.26%
0%
17.26%
3 Years
3058.67%
0%
3058.67%
4 Years
-91.46%
0%
-91.46%
5 Years
-81.68%
0%
-81.68%

VistaGen Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is VistaGen Therapeutics, Inc. technically bullish or bearish?

As of 26 August 2025, the technical trend for VistaGen Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, indicating positive momentum. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a bearish stance on the monthly timeframe. The KST is bullish weekly but bearish monthly, while the Dow Theory indicates a mildly bullish trend in both weekly and monthly perspectives. The OBV presents a mixed view, being mildly bearish weekly but bullish monthly. In terms of performance, VistaGen has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of 3.05% versus 12.22% for the S&P 500, and a one-year return of 1.50% compared to 17.14% for the index. Overall, the current technical stance is bullish, but the strength is mixed, with some indicators showing caution....

Read More

Is VistaGen Therapeutics, Inc. overvalued or undervalued?

As of 8 July 2024, the valuation grade for VistaGen Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.84 and an EV to EBITDA ratio of 0.37, which suggest that the market may not be accurately reflecting the underlying value of the company. Additionally, the ROCE stands at an impressive 773.04%, but this is overshadowed by a negative ROE of -58.31%, indicating challenges in generating returns for shareholders. In comparison to its peers, VistaGen's valuation ratios are concerning, with Solid Biosciences, Inc. showing a worse EV to EBITDA of -0.8654 and Cognition Therapeutics, Inc. at -3.8036, both indicating significant struggles in profitability. The company's stock performance has also lagged behind the S&P 500, with a 5-ye...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.84%
EBIT Growth (5y)
-197.22%
EBIT to Interest (avg)
-38.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.14
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
70.82%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.84
EV to EBIT
0.37
EV to EBITDA
0.37
EV to Capital Employed
2.86
EV to Sales
-19.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
773.04%
ROE (Latest)
-58.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 16 Schemes (9.68%)

Foreign Institutions

Held by 18 Foreign Institutions (4.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.09% vs -8.46% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.60",
          "val2": "-15.00",
          "chgp": "-4.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.10",
          "val2": "-14.10",
          "chgp": "-7.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-64,770.50%",
          "val2": "-64,615.40%",
          "chgp": "-15.51%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -54.55% vs 650.00% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -74.83% vs 50.34% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "1.10",
          "chgp": "-54.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-55.30",
          "val2": "-32.50",
          "chgp": "-70.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.40",
          "val2": "-29.40",
          "chgp": "-74.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-115,170.80%",
          "val2": "-31,034.80%",
          "chgp": "-8,413.60%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Dec'24
Change(%)
Net Sales
0.20
0.20
Operating Profit (PBDIT) excl Other Income
-15.60
-15.00
-4.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.10
-14.10
-7.09%
Operating Profit Margin (Excl OI)
-64,770.50%
-64,615.40%
-15.51%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -7.09% vs -8.46% in Dec 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.50
1.10
-54.55%
Operating Profit (PBDIT) excl Other Income
-55.30
-32.50
-70.15%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-51.40
-29.40
-74.83%
Operating Profit Margin (Excl OI)
-115,170.80%
-31,034.80%
-8,413.60%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -54.55% vs 650.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -74.83% vs 50.34% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About VistaGen Therapeutics, Inc. stock-summary
stock-summary
VistaGen Therapeutics, Inc.
Pharmaceuticals & Biotechnology
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).
Company Coordinates stock-summary
Company Details
343 Allerton Ave , SOUTH SAN FRANCISCO CA : 94080-4816
stock-summary
Tel: 1 650 57736001 212 8961254
stock-summary
https://www.vistagen.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."